Er-Kim Announces LOQTORZI® (toripalimab) Included on Poland’s Ministry of Health Reimbursement List
WARSAW, NY, POLAND, August 11, 2026 /EINPresswire.com/ -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, is pleased to announce the inclusion of LOQTORZI® (toripalimab) on the July 1st reimbursement list by the Polish Ministry of Health.
This regulatory and reimbursement listing ensures that patients in Poland will now have funded access to treatments for two distinct, hard-to-treat malignancies. This includes patients battling nasopharyngeal carcinoma (NPC) - a rare, aggressive, and historically underserved head and neck cancer – as well as those with advanced, recurrent, or metastatic Oesophageal Squamous Cell Carcinoma (OSCC) that cannot be removed by surgery.
The successful inclusion of LOQTORZI® (toripalimab) on the national list underscores the operational strength of the strategic alliance between LEO Pharma A/S and Er-Kim, its commercialization partner for the region. The partnership leverages the combined regulatory, market access, and commercial expertise of both organizations to bridge critical gaps in specialized care across Central and Eastern Europe.
"This achievement is a true testament to the power of a shared vision,” said Cem Zorlular, Chief Executive Officer of Er-Kim. "By combining forces with LEO Pharma, we are fulfilling our commitment to accelerate patient access to highly innovative treatments and ensuring that rare oncology populations are no longer left behind."
The Ministry of Health's July 1st list introduces 25 new therapies to the Polish market, with a distinct focus on expanding precise oncology care and addressing unmet needs in rare and ultra-rare diseases.
In 2025, LEO Pharma A/S was granted exclusive distribution and sales rights for LOQTORZI® in the European Union (EU), the European Economic Area (EEA), as well as Switzerland and the United Kingdom, while TopAlliance Biosciences remains the Marketing Authorisation Holder (MAH).
About Er-Kim
Established in 1981, Er-Kim stands at the forefront of biopharmaceutical innovation, setting new commercialization and patient access standards. Through strategic partnerships with over 40 global leaders, Er-Kim distributes more than 68 products to 50+ countries, revolutionizing patient care in international markets by solving complex distribution challenges. Er-Kim has a dedicated team of over 400 professionals worldwide and revenues exceeding EUR 390M. For more information, please visit www.er-kim.com.
This regulatory and reimbursement listing ensures that patients in Poland will now have funded access to treatments for two distinct, hard-to-treat malignancies. This includes patients battling nasopharyngeal carcinoma (NPC) - a rare, aggressive, and historically underserved head and neck cancer – as well as those with advanced, recurrent, or metastatic Oesophageal Squamous Cell Carcinoma (OSCC) that cannot be removed by surgery.
The successful inclusion of LOQTORZI® (toripalimab) on the national list underscores the operational strength of the strategic alliance between LEO Pharma A/S and Er-Kim, its commercialization partner for the region. The partnership leverages the combined regulatory, market access, and commercial expertise of both organizations to bridge critical gaps in specialized care across Central and Eastern Europe.
"This achievement is a true testament to the power of a shared vision,” said Cem Zorlular, Chief Executive Officer of Er-Kim. "By combining forces with LEO Pharma, we are fulfilling our commitment to accelerate patient access to highly innovative treatments and ensuring that rare oncology populations are no longer left behind."
The Ministry of Health's July 1st list introduces 25 new therapies to the Polish market, with a distinct focus on expanding precise oncology care and addressing unmet needs in rare and ultra-rare diseases.
In 2025, LEO Pharma A/S was granted exclusive distribution and sales rights for LOQTORZI® in the European Union (EU), the European Economic Area (EEA), as well as Switzerland and the United Kingdom, while TopAlliance Biosciences remains the Marketing Authorisation Holder (MAH).
About Er-Kim
Established in 1981, Er-Kim stands at the forefront of biopharmaceutical innovation, setting new commercialization and patient access standards. Through strategic partnerships with over 40 global leaders, Er-Kim distributes more than 68 products to 50+ countries, revolutionizing patient care in international markets by solving complex distribution challenges. Er-Kim has a dedicated team of over 400 professionals worldwide and revenues exceeding EUR 390M. For more information, please visit www.er-kim.com.
Rosalia Scampoli
Marketcom PR
+ +1 9148151465
rscampoli@marketcompr.com
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.